Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4358115

CC(C)(C)c1ccc(C(=O)Nc2ccc3cc2CCc2cccc(c2)Nc2ncc(Cl)c(n2)N3)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 11/20 0.52
STK4 Q13043 1/20 0.40
STK3 Q13188 1/20 0.40
STK26 Q9P289 1/20 0.40
STK24 Q9Y6E0 1/20 0.40
JAK2 O60674 10/20 0.40
JAK1 P23458 10/20 0.40
JAK3 P52333 10/20 0.40
TYK2 P29597 9/20 0.40
PPARG P37231 1/20 0.37
NR1H4 Q96RI1 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GLA P06280 1/20 0.37
RAB9A P51151 1/20 0.37
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4361123 0.95 ALK (0.56) ALKSTK4STK3STK26STK24
Trifluoroacetic Acid SCHEMBL4364803 0.91 ALK (0.51) ALKSTK4STK3STK26STK24
Trifluoroacetic Acid SCHEMBL4360425 0.91 ALK (0.50) ALKSTK4STK3STK26STK24
SCHEMBL4362558 0.90 ALK (0.54) ALKSTK4STK3STK26STK24
SCHEMBL4366625 0.88 ALK (0.58) ALKSTK4STK3STK26STK24
Trifluoroacetic Acid SCHEMBL4371097 0.88 ALK (0.53) ALKSTK4STK3STK26STK24
SCHEMBL4361863 0.87 ALK (0.53) ALKSTK4STK3STK26STK24
SCHEMBL4360159 0.87 ALK (0.58) ALKSTK4STK3STK26STK24
SCHEMBL1076247 0.87 ALK (0.56) ALKSTK4STK3STK26STK24
SCHEMBL4366199 0.87 ALK (0.57) ALKSTK4STK3STK26STK24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK ALK 3/4885STK4 174/4885STK3 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.